Biopharmaceutical company Acurx Pharmaceuticals LLC revealed on Wednesday the receipt of the US Food and Drug Administration's Fast Track designation to facilitate the development and expedite the regulatory pathway of the investigational new treatment 362E for Clostridium difficile Infection (CDI).
The company said ACX-362E is a novel, first-in-class, orally-administered antibacterial. It is the first of a novel class of DNA polymerase IIIC inhibitors under development to treat bacterial infections. It plans completing its Phase 1 clinical trial in the Q2 2019 and advance it into a Phase 2 clinical trial in the Q4 2019.
Under the US FDA's QIDP designation, ACX-362E will now be eligible to benefit from certain incentives for the development of new antibiotics provided under the Generating Antibiotic Incentives Now Act (the GAIN Act). These incentives include Priority Review and eligibility for Fast Track status as well as an additional five-year extension of Hatch-Waxman marketing exclusivity.
According to the company, ACX-362E is being developed as a targeted, narrow spectrum oral antibiotic for the treatment of patients with CDI.
In conjunction, the CDC has reported nearly 500,000 patients per year treated for CDI in the US alone, with a recurrence rate at 20% to 30%, with limited antibiotics available to treat patients. CDI is also prevalent in Europe, Japan and Canada. CDI is a life-threatening condition with persistent unmet medical need.
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Astellas Pharma's CRESEMBA receives orphan drug and paediatric exclusivity from FDA
SK Biopharmaceuticals' cenobamate achieves 100,000 patient treatment milestone
Calliditas Therapeutics' Nefecon receives additional seven years orphan drug exclusivity from US FDA
Merck finalises acquisition of Harpoon Therapeutics Inc
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Celltrion USA submits CT-P39 Biologics License Application to FDA
iOnctura's first-in-class autotaxin cancer therapy granted US FDA Orphan Drug Designation
Epitomee submits Weight Loss Capsule for FDA approval in US
Calliditas Therapeutics TARPEYO receives seven years orphan drug exclusivity from US FDA
Camurus reports Oclaiz NDA accepted by FDA for acromegaly treatment
TME Pharma plans NOX-A12 Phase 2 trial in brain cancer after FDA IND clearance